APT Medical Inc. (SHA:688617)
407.68
+20.38 (5.26%)
Apr 1, 2025, 2:45 PM CST
APT Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
Operating Revenue | 2,066 | 1,642 | 1,204 | 822.86 | 477.94 | Upgrade
|
Other Revenue | - | 8.49 | 11.55 | 5.82 | 1.5 | Upgrade
|
Revenue | 2,066 | 1,650 | 1,216 | 828.69 | 479.44 | Upgrade
|
Revenue Growth (YoY) | 25.18% | 35.71% | 46.74% | 72.85% | 18.68% | Upgrade
|
Cost of Revenue | - | 486.14 | 354.04 | 259.08 | 142.13 | Upgrade
|
Gross Profit | 2,066 | 1,164 | 861.98 | 569.61 | 337.3 | Upgrade
|
Selling, General & Admin | - | 386.96 | 307.57 | 251.43 | 152.5 | Upgrade
|
Research & Development | - | 237.92 | 174.88 | 134.88 | 71.9 | Upgrade
|
Other Operating Expenses | 1,312 | 14.52 | 13.75 | 8.14 | 6.14 | Upgrade
|
Operating Expenses | 1,312 | 639.21 | 496.99 | 393.93 | 230.82 | Upgrade
|
Operating Income | 754.02 | 524.86 | 364.99 | 175.68 | 106.48 | Upgrade
|
Interest Expense | - | -3.69 | -1.45 | -1.63 | -0.83 | Upgrade
|
Interest & Investment Income | - | 27.74 | 23.94 | 13.26 | 1.21 | Upgrade
|
Currency Exchange Gain (Loss) | - | 2.66 | 1.17 | -1 | -0.43 | Upgrade
|
Other Non Operating Income (Expenses) | -7.72 | -0.04 | -0.49 | -0.5 | -0.33 | Upgrade
|
EBT Excluding Unusual Items | 746.29 | 551.53 | 388.16 | 185.81 | 106.09 | Upgrade
|
Impairment of Goodwill | - | -3.84 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | 0.34 | 21.72 | -0.07 | Upgrade
|
Gain (Loss) on Sale of Assets | - | 11.97 | 0.06 | 0.02 | -0.23 | Upgrade
|
Asset Writedown | - | -0.12 | -10.68 | -3.57 | - | Upgrade
|
Other Unusual Items | - | 36.83 | 17.25 | 17.58 | 15.42 | Upgrade
|
Pretax Income | 746.29 | 596.37 | 395.13 | 221.55 | 121.21 | Upgrade
|
Income Tax Expense | 72.82 | 74.24 | 54.98 | 26.7 | 17.02 | Upgrade
|
Earnings From Continuing Operations | 673.48 | 522.13 | 340.16 | 194.85 | 104.19 | Upgrade
|
Minority Interest in Earnings | - | 11.79 | 17.86 | 13.07 | 6.58 | Upgrade
|
Net Income | 673.48 | 533.92 | 358.02 | 207.92 | 110.78 | Upgrade
|
Net Income to Common | 673.48 | 533.92 | 358.02 | 207.92 | 110.78 | Upgrade
|
Net Income Growth | 26.14% | 49.13% | 72.19% | 87.70% | 34.15% | Upgrade
|
Shares Outstanding (Basic) | 97 | 96 | 96 | 95 | 72 | Upgrade
|
Shares Outstanding (Diluted) | 97 | 98 | 98 | 95 | 72 | Upgrade
|
Shares Change (YoY) | -1.01% | -0.20% | 2.99% | 31.44% | -0.29% | Upgrade
|
EPS (Basic) | 6.96 | 5.54 | 3.71 | 2.20 | 1.53 | Upgrade
|
EPS (Diluted) | 6.96 | 5.46 | 3.66 | 2.19 | 1.53 | Upgrade
|
EPS Growth | 27.42% | 49.43% | 67.19% | 42.80% | 34.55% | Upgrade
|
Free Cash Flow | - | 487.03 | 224.25 | 14.01 | 104.04 | Upgrade
|
Free Cash Flow Per Share | - | 4.98 | 2.29 | 0.15 | 1.44 | Upgrade
|
Dividend Per Share | - | 1.379 | 1.138 | 0.690 | 0.345 | Upgrade
|
Dividend Growth | - | 21.21% | 64.98% | 100.03% | - | Upgrade
|
Gross Margin | 100.00% | 70.54% | 70.88% | 68.74% | 70.35% | Upgrade
|
Operating Margin | 36.50% | 31.81% | 30.01% | 21.20% | 22.21% | Upgrade
|
Profit Margin | 32.60% | 32.36% | 29.44% | 25.09% | 23.11% | Upgrade
|
Free Cash Flow Margin | - | 29.51% | 18.44% | 1.69% | 21.70% | Upgrade
|
EBITDA | 809.23 | 580.08 | 405.69 | 203.49 | 126.49 | Upgrade
|
EBITDA Margin | 39.17% | 35.15% | 33.36% | 24.56% | 26.38% | Upgrade
|
D&A For EBITDA | 55.22 | 55.22 | 40.7 | 27.81 | 20 | Upgrade
|
EBIT | 754.02 | 524.86 | 364.99 | 175.68 | 106.48 | Upgrade
|
EBIT Margin | 36.50% | 31.80% | 30.01% | 21.20% | 22.21% | Upgrade
|
Effective Tax Rate | 9.76% | 12.45% | 13.91% | 12.05% | 14.04% | Upgrade
|
Revenue as Reported | - | 1,650 | 1,216 | 828.69 | 479.44 | Upgrade
|
Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.